Our interdisciplinary team of cancer researchers, bioinformaticians, and data scientists uses in-house developed custom algorithms that include complex mathematical and statistical models for in-depth curation and correlation of published scientific findings and clinical research to provide the most updated and best treatment recommendations.
Recognizing the unique strengths of both solid and liquid biopsies, 4baseCare’s SoLiQ combines these methods to deliver a comprehensive genomic profile of the tumor. This dual approach enhances mutation detection accuracy, facilitates continuous monitoring, and provides a deeper understanding of tumor evolution. By integrating solid and liquid biopsy data, SoLiQ empowers precision oncology, ensuring adaptive and effective treatment strategies.
Somatic mutation tests in cancer are typically performed on tumor tissue (FFPE block/Fresh tissue) to identify somatic mutations, which might help identify the clinically actionable genomic alterations for cancer patients. Our TARGT (Tumor-Associated Drug Response by Genomic Testing) portfolio of genomic tests is validated to identify somatic mutations in the tumor tissue with high sensitivity and specificity to detect even low-frequency genomic alterations/aberrations/mutations that drive cancer.
All the tests under the TARGT portfolio identify genomic variants associated with approved treatment and clinical trials. TARGT tests report actionable and targetable somatic mutations, which include SNVs, Indels, CNAs, Gene fusions/Splice variants, and Genomic Signatures like Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI).
Liquid biopsy is a minimally invasive blood-based assay that has a role in monitoring, prognostication, and therapeutic treatment-related decisions for cancer patients. The assay isolates and detects tumor genomes and associated genomic alterations such as SNVs/InDels, CNAs, and Gene Fusions/Splice Variants from peripheral blood (ctDNA).
Liquid biopsies have been recognized as valuable diagnostic and monitoring tools. With FDA approving the use of liquid biopsies for Non-Small Cell Lung Cancer and other solid tumors, oncologists around the globe are utilizing this technique for various cancer patients.
Compared to tissue biopsies, liquid biopsies are quicker, easier, less painful, and minimally invasive as they require only the patient’s blood for further analysis. The technique involves extracting tumor DNA from blood followed by NGS analysis for precise cancer management.
Genomic variations/mutations/aberrations in the genes you are born with can increase your cancer risk. Our NGS (Next-Generation Sequencing) based Hereditary Cancer genetic panels analyze genes associated with cancer risk DDR (DNA Damage Repair), Mismatch Repair (MMR), and HRR (Homologous Recombination Repair) pathways. The panel includes genes associated with familial and hereditary cancers (Breast, Ovarian, Prostate, Pancreatic, Colon, etc).
As per ACMG guidelines, the detected variants are classified as pathogenic, likely pathogenic, VUS (Variant of Unknown Significance), likely benign, and benign. This may contribute to a high, moderate, or low cancer risk.
Some of the Germline variants, like in the BRCA gene, help identify cancer risk and help in making PARP (Poly-ADP-Ribose Polymerase) inhibitor targeted therapy treatment decisions.
Discover how our advanced genomic solutions can transform cancer care.
Consult with our specialists today to identify the best test for you.
Consult our Experts to find the right test for you.
Kindly fill the form below to download our Liquid Biopsy Portfolio brochure :